A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
Public ClinicalTrials.gov record NCT03711162. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study was to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study also investigated how well GLPG1690 is tolerated (for example if you got any side effects while on study drug).
Study identification
- NCT ID
- NCT03711162
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 525 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 27, 2018
- Primary completion
- Mar 29, 2021
- Completion
- Mar 29, 2021
- Last update posted
- Jul 28, 2022
2018 – 2021
United States locations
- U.S. sites
- 47
- U.S. states
- 29
- U.S. cities
- 45
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pulmonary Associates | Phoenix | Arizona | 85006 | — |
| Mayo Clinic Arizona - PPDS | Scottsdale | Arizona | 85259 | — |
| Atria Clinical Research - BTC - PPDS | Little Rock | Arkansas | 72209 | — |
| David Geffen School of Medicine at UCLA | Los Angeles | California | 90095 | — |
| Respire Research | Palm Springs | California | 92262 | — |
| University of California San Diego | San Diego | California | 92037 | — |
| Stanford University Medical Center | Stanford | California | 94305 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| National Jewish Health | Denver | Colorado | 80206 | — |
| Western Connecticut Medical Group | Danbury | Connecticut | 06810 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06510 | — |
| MedStar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| PAB Clinical Research - ClinEdge - PPDS | Brandon | Florida | 33511 | — |
| St. Francis Medical Institute - BTC - PPDS | Clearwater | Florida | 33765 | — |
| North Florida/South Georgia Veterans Health System-NAVREF-PPDS | Gainesville | Florida | 32608 | — |
| University of Florida | Gainesville | Florida | 32610 | — |
| Advanced Pulmonary Research Institute | Loxahatchee Groves | Florida | 33470 | — |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | — |
| Pulmonary and Infections Disease Associates | Council Bluffs | Iowa | 51503 | — |
| University of Louisville | Louisville | Kentucky | 40202 | — |
| Tulane Medical Center | New Orleans | Louisiana | 70112 | — |
| University of Maryland Medical Center | Baltimore | Maryland | 21201 | — |
| Massachusetts General Hospital, Division of Pulmonary and Critical Care Medicine | Boston | Massachusetts | 02114 | — |
| Caritas St. Elizabeth's Medical Center | Boston | Massachusetts | 02135 | — |
| Henry Ford Health System | Dearborn | Michigan | 48124 | — |
| Minnesota Lung Center | Minneapolis | Minnesota | 55407 | — |
| Mayo Clinic - PPDS | Rochester | Minnesota | 55905 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Creighton University | Omaha | Nebraska | 68131 | — |
| University of Rochester Medical Center - PPDS | Rochester | New York | 14642 | — |
| PulmonIx LLC | Greensboro | North Carolina | 27403 | — |
| UC Health Department of Internal Medicine, Pulmonary, Critical Care & Sleep Medicine | Cincinnati | Ohio | 45267 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195-0001 | — |
| The Oregon Clinic | Portland | Oregon | 97220 | — |
| Penn State Milton S Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Houston Methodist Hospital | Houston | Texas | 77030 | — |
| Metroplex Pulmonary and Sleep Medicine Center | McKinney | Texas | 75069 | — |
| University of Texas Health Science Center San Antonio | San Antonio | Texas | 78229 | — |
| University of Utah Medical Care | Salt Lake City | Utah | 84108 | — |
| University of Virginia | Charlottesville | Virginia | 22908 | — |
| Western Washington Medical Group | Everett | Washington | 98208 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
| University of Wisconsin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 85 non-U.S. sites.
Recently updated Idiopathic Pulmonary Fibrosis trials
Other public records listing Idiopathic Pulmonary Fibrosis. Sorted by last update posted; newest first. Not a recommendation.
- NCT07520110: Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis Not yet recruiting
- NCT06325696: H01 in Adults With Interstitial Lung Disease (The SOLIS Study) Recruiting
- NCT05389215: Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF Active, not recruiting
- NCT07671911: Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets Recruiting
- NCT07674745: Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis Not yet recruiting
- NCT05241275: Xenon MRI and Progressive ILD Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03711162, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 28, 2022 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03711162 live on ClinicalTrials.gov.